The focus of the industry on living human beings and highly controlled standards make it a unique challenge for business leaders. These aspects make the industry a natural source of innovation, leading to some major breakthroughs that have improved agricultural yields, created biofuels, and even led to life-saving pharmaceutical products.

When it comes to revenue-generating strategies biotech start-ups have numerous options. Most choose a technology partnership or an asset creation-and-out licensing strategy. Technology partnering offers faster revenue, but with less risk of financial loss, while out-licensing and asset creation strategy can yield significantly higher returns when it’s successful. A growing number genotec-frankfurt.de of biotechs at the early stages of research employ a hybrid strategy that combines these two approaches.

People who opt for a product-centric strategy can achieve commercial success in the event that they manage to get their pipelines up to the right level, and attract a big pharmaceutical partner or an investor with a large sum of money. It can be expensive but making sure that you balance opportunistic methods to leverage outside assets with the right research-based decision making about homegrown projects is essential.

The “platform” model is a second alternative to generate revenue. It is less expensive than product-oriented development, but involves significant risk. In this model biotechs have the ability to develop their platform technology before partnering up with big pharma to create a portfolio of drug discovery initiatives that target specific diseases (i.e. disease x is a biological condition that causes). This is the method Advinus Therapeutics and a few others have taken.